IQVIA HOLDINGS INC. (IQV): what the price assumes

In the published model solve dated 2026-Q2, anchored at $261.75, IQVIA HOLDINGS INC. (IQV) is priced for +21.4% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/IQV

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.8% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.0%); the inversion above states its own rate.

Per-Model Detail (n=14)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• IQVIA is the dominant data-and-services partner to the drug industry: it runs clinical trials as a contract research organization and sells the prescription and patient data that pharma uses to make decisions, two businesses that feed each other.
• The most recent quarter was strong, with revenue up 8.4% to $4.15 billion, R&D net new bookings climbing to $2.5 billion, and the company raising its full-year EPS guidance.
• The defining risk is leverage plus client budgets: net debt near $14 billion keeps interest coverage around 3 times, and biopharma R&D spending is the demand variable IQVIA does not control.

Bull Case

The clearest window into IQVIA is its capital allocation, because it shows what management believes its own stock is worth and how the business converts revenue into shareholder value. Even while carrying significant debt, the company has been reducing its share count, down about 3% a year, which means it is buying back stock rather than diluting, deploying cash flow into its own equity. That is a deliberate signal: management is choosing per-share value over empire-building, funded by the steady cash a services-and-data business throws off.

The business underneath is a genuine two-sided moat. On one side, IQVIA is one of the largest contract research organizations, running the clinical trials that drug companies increasingly outsource rather than staff internally. On the other, it owns one of the deepest commercial datasets in healthcare, the prescription, sales, and patient-level information pharma relies on to target and measure its products. The two reinforce each other: trial relationships generate data, and data insight wins trial work. The most recent quarter showed both engines running, with Commercial Solutions up 11.6% and R&D Solutions up 6.2%, and R&D net new bookings rising to $2.5 billion from $2.2 billion a year earlier at a book-to-bill above 1. Bookings outpacing revenue is the leading indicator of future growth, and the backlog converts roughly $8.9 billion to revenue over the next year.

The outsourcing tailwind is the durable part of the thesis. Drug companies face pressure to develop more therapies with leaner internal teams, and the 10-K points to "outsourcing trends in the biopharmaceutical industry" as a driver of demand for IQVIA's services. As pharma pushes more of its R&D and commercial work to specialized partners, the largest, most data-rich partner captures a disproportionate share. The company raised full-year EPS guidance on the strong quarter, and the stock rallied on the print, reflecting confidence that the bookings momentum carries forward.

Bear Case

The moat-erosion risk worth taking seriously is that IQVIA's data advantage, the thing that has set it apart, is being chipped at from two directions. The 10-K itself warns of "increased competition from firms that may have lower costs to market (e.g., no data supply costs)", competitors who can undercut IQVIA precisely because they do not carry the expense of assembling and licensing the data IQVIA is proud of. As more healthcare data becomes available and AI lowers the cost of analyzing it, the premium IQVIA charges for its proprietary insight faces pressure. The asset that justifies the premium multiple is exactly the one technology and new entrants are working to commoditize.

The demand side is outside the company's control and currently under strain. IQVIA's revenue depends on how much the drug industry spends on clinical trials and commercial analytics, and biopharma clients are facing budget pressure. Smaller and mid-sized biotechs, a meaningful source of trial work, are sensitive to the funding environment, and when biotech funding tightens, trial starts slow and bookings can soften. The 10-K also names a structural conflict: relationships with clients "who are in competition with each other may adversely impact the degree to which other clients" use IQVIA's services. Being everyone's partner in a competitive industry has limits.

The balance sheet is where the bear bites hardest if demand wavers. IQVIA carries net debt of roughly $14 billion, more than six times trailing operating income, with interest coverage around 3 times. The price is reached only by the relative-multiple and forward-growth methods; the asset-based and earnings-power lenses say it is expensive. So a buyer is paying a growth-supported multiple for a levered company whose growth depends on a client base under budget pressure. If bookings decelerate or biopharma spending contracts, the leverage that is manageable in good times becomes the amplifier on the downside. The business is excellent and currently executing well, but the price assumes that execution and the spending environment both continue.

Valuation

IQVIA is priced as a quality compounder in healthcare services, and the price embeds an assumption of high-single-digit forward growth carried by the backlog and the outsourcing tailwind. The inversion implies roughly 9% growth, which is close to the 8.4% revenue growth the company just printed, so the assumption is grounded in current results rather than a stretch.

The methods split along the usual line for an asset-light services franchise. The relative-multiple and forward-growth families reach the price; the asset-based and earnings-power lenses sit below it and call the stock expensive. For a business whose value is its data, its client relationships, and its $8.9 billion of convertible backlog rather than its physical assets, that pattern is expected. The premium is the durability premium on the outsourcing-and-data moat, and it holds as long as bookings keep outpacing revenue, which they did this quarter at a book-to-bill above 1. Among the contract-research and life-science-services peers, IQVIA is valued on the strength of its backlog and data assets rather than on a re-rating thesis.

Solvency is the constraint that keeps the bull honest. IQVIA carries net debt of roughly $14 billion, more than six times trailing operating income, with interest coverage around 3 times. That leverage is serviceable while the business grows and generates cash, and the company has used that cash to buy back stock, shrinking the share count about 3% a year. But it is the amplifier on the downside: if biopharma spending contracts or bookings decelerate, the debt that is comfortable in a strong market becomes the pressure point. The decisive variable is the trajectory of client R&D budgets, because that determines whether the backlog keeps refilling at the pace the price assumes.

Catalysts

The most recent quarter, the first of 2026, beat expectations and prompted a guidance raise. Revenue rose 8.4% year over year to $4.151 billion, ahead of consensus, with adjusted diluted EPS of $2.90 up 7.4%, and the stock rallied roughly 9% on the print. Commercial Solutions grew 11.6% and R&D Solutions 6.2%, while adjusted EBITDA reached $932 million.

The forward-looking signal was the bookings. R&D net new bookings climbed to $2.5 billion from $2.2 billion a year earlier, a book-to-bill of 1.04, and the backlog set up roughly $8.9 billion of conversion to revenue over the next twelve months. IQVIA reaffirmed full-year revenue and adjusted EBITDA guidance while raising its full-year adjusted EPS range to $12.65 to $12.95.

The forward watch items center on the biopharma spending environment. Management framed the results as resilience even as clients face budget pressure and lean on AI-driven efficiencies. Because the company's growth depends on how much the drug industry spends on trials and analytics, the pace of net new bookings each quarter, and any shift in biotech funding, are the catalysts that confirm or challenge the backlog-driven outlook.

Peer Cohorts (Per Segment, With Filing Citations)

Technology & Analytics Solutions (reported)

• VEEV (Veeva Systems Inc.)
• FY2025 10-K: …content management, field optimization, and commercial insights and analytics. R&D Business Consulting enables continuous and sustainable innovation across the drug development value chain, including process efficiency, time-to-market acceleration, and optimized operating model and governance. Our Customers As of…
• FY2025 10-K: …data and data analytics providers. No single vendor offers products that compete with all of our Veeva Development Cloud or Quality Cloud applications, but IQVIA, Dassault Systèmes, OpenText Corporation, Oracle Corporation, Honeywell International Inc., and other smaller application providers offer applications that…
• DOCS (Doximity, Inc.)
• FY2025 10-K: …We provide Hiring Solutions customers access to our platform which enables them to post job openings or deliver a fixed number of monthly messages to our network of medical professionals. We offer Workflow Solutions customers access to telehealth tools, on-call scheduling, and our AI writing assistant during the…
• FY2025 10-K: …to articles about scientific congresses or professional meetings. We take a rigorous approach to launching new modules, including internal and customer pilots. Our goal is to make sponsored content useful, relevant, and informative for our members. Our newer integrated programs allow our clients to leverage the power…
• CLVT (CLARIVATE PLC)
• FY2025 10-K: …by harnessing the power of human ingenuity. From research and learning to commercialization, we offer intelligence solutions, workflow solutions, and tech-enabled services to customers in the Academia & Government, Intellectual Property, and Life Sciences & Healthcare end markets. • Intelligence solutions.…
• FY2025 10-K: …segments: Academia & Government ("A&G"), Intellectual Property ("IP"), and Life Sciences & Healthcare ("LS&H"), based on the different products and services we offer and the markets we serve. Academia & Government Our A&G segment connects trusted content, responsible technology, and editorial expertise to fuel…

Research & Development Solutions / Contract Sales & Medical Solutions (reported)

• ICLR (ICON plc)
• FY2025 20-F: …impact on our results of operations. Unsatisfied Performance Obligation Our unsatisfied performance obligation consists of contracted revenue yet to be earned from projects awarded by clients. At December 31, 2025, we had contracted unsatisfied performance obligations of $14.9 billion (December 31, 2024: $15.9…
• FY2025 20-F: …management and randomization control. • Interactive Response Technology - ICON's interactive response technology for centralized patient randomization, drug inventory management and multi-channel data capture via phone, browser or mobile. • CARD - Cloud-based platform that simplifies end-of-study clinical archive…
• MEDP (Medpace Holdings, Inc.)
• FY2025 10-K: …customized campaigns and web-site development, conference planning and lead generation through market research and business intelligence analysis. All of our sales and marketing data are housed within a third party customer relationship management tool that provides us the analytics we need to make sales planning and…
• FY2025 10-K: …pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics. We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our…
• CRL (CHARLES RIVER LABORATORIES INTERNATIONAL, INC.)
• FY2025 10-K: Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). Our RMS reportable segment includes the products and services offered within Research Models, Research Model Services, and Cell Solutions. Research Models includes the commercial production and sale of small research models, as well as…
• FY2025 10-K: DL™) offerings, where we provide vivarium space to our clients. Some research institutions prefer to retain certain elements of their research in-house, while outsourcing staffing and management, thus driving demand for our services. We believe that our expertise in early-stage drug research, and in particular…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.